CFAE/Spatiotemporal Dispersion Guided Ablation Versus PVI Guided Ablation in Persistent AF (CIPA)
Complex Fractionated Atrial Electrocardiograms (CFAEs) Spatiotemporal Dispersion Guided Ablation Versus Pulmonary Vein Isolation (PVI) Guided Ablation in Persistent Atrial Fibrillation, a Multicenter Randomized Trial
Sponsor: Biosense Webster, Inc.
This NA trial investigates Chronic Atrial Fibrillation and is currently ongoing. Biosense Webster, Inc. leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Sep 2022 — Jul 2024 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Recruiting NA
-
Jun 2020 — Jan 2021 [monthly]
Recruiting NA
-
Nov 2018 — Jun 2020 [monthly]
Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2017 [monthly]
Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biosense Webster, Inc.
- Diagram B.V.
- Johnson & Johnson
For direct contact, visit the study record on ClinicalTrials.gov .